Meet Henrijette
Henrijette Richter is a Managing Partner at Sofinnova Partners, a leading European venture capital firm.
She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Freya Biosciences, Muna Therapeutics, Nitrase Therapeutics, NodThera, Delinia (sold to Celgene), and iOmx Therapeutics.
Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead).
Henrijette started her career in venture more than 20 years ago when she joined Sunstone Capital from her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Henrijette is part of several advisory boards including the SUND Advisory Board (University of Copenhagen), The Sanger Venture Advisory Group, and is part of the Invest Europe VC Council.
Henrijette holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.
